Cardiovascular Disease
Lilly
FAQs
Register
Contact Us
 

Cardiovascular Disease



  1. Pharmacokinetics and Pharmacodynamics Following Maintenance Doses of Prasugrel and Clopidogrel in Chinese Carriers of CYP2C19 Variants. Ronan P. Kell, Sandra L. Close, Nagy A. Farid, Kenneth J. Winters, Lei Shen, Fanni Natanegara, Joseph A. Jakubowski, Mary Ho, Joseph R. Walker, David S. Small. Br J Clin Pharmacol. 2012 Jan;73(1):93-105

  2. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R. Clinical Therapeutics 2010 Feb;32(2):365-79.

  3. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):3-24. Epub 2009 Nov 26.